Generate Biomedicines Inc (NASDAQ:GENB) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Generate Biomedicines Inc (NASDAQ:GENB) have been given an average rating of “Moderate Buy” by the seven ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $25.40.

A number of research firms have recently commented on GENB. Piper Sandler began coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating and a $24.00 target price for the company. The Goldman Sachs Group started coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $26.00 target price for the company. HC Wainwright increased their price target on Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a report on Friday, May 8th. Guggenheim started coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set a “buy” rating and a $30.00 price target on the stock. Finally, Morgan Stanley increased their price target on Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, May 14th.

Generate Biomedicines Stock Down 12.4%

NASDAQ GENB opened at $12.87 on Friday. Generate Biomedicines has a one year low of $11.00 and a one year high of $16.75. The firm’s 50 day moving average price is $13.19.

Generate Biomedicines (NASDAQ:GENB) last posted its earnings results on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.